AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4
slide-5

Ignalis-M 100/500 Tablet ER

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Sitagliptin (100mg) + Metformin (500mg)

Overview Ignalis-M 100/500 Tablet ER

Duo-Med 100/500 Extended-Release tablets combine two medications to manage elevated blood glucose in individuals with type 2 diabetes. This dual action helps prevent serious diabetic complications like kidney failure and vision loss, and may lessen the risk of cardiovascular events. Duo-Med 100/500 ER may be used independently or in conjunction with other antidiabetic therapies. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is personalized based on your health status, glucose readings, and other medications. Consuming it with meals minimizes gastrointestinal discomfort. Consistent daily dosing, at the same time each day, maximizes effectiveness; discontinuation should only occur under physician guidance. Adherence to your prescribed diet and exercise plan is crucial. Your lifestyle significantly impacts diabetes control. Commonly reported side effects include diarrhea, nausea, vomiting, indigestion, headache, and pharyngitis. Hypoglycemia is a potential adverse effect, particularly when combined with insulin or sulfonylureas; therefore, understanding its recognition and management is essential. This medication isn't universally suitable. Prior to use, inform your doctor of any history of renal, hepatic, or cardiac disease, pancreatic issues, or significant alcohol consumption. Pregnant or lactating women should seek medical counsel before use. Interactions with other medications are possible; therefore, disclose all medications to your physician to ensure safety. Alcohol consumption should be minimized due to its hypoglycemic effects. Your doctor will monitor renal function and blood sugar levels before, during, and after treatment.

Primary Ingredients of Ignalis-M 100/500 Tablet ER

No text provided. Please provide the text you wish me to rephrase.

Uses of Ignalis-M 100/500 Tablet ER

Managing type 2 diabetes

Major Benefits of Ignalis-M 100/500 Tablet ER:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. The Ignalis-M 100/500 Tablet ER should be administered with a meal.

Common Side effects of Ignalis-M 100/500 Tablet ER:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Ignalis-M 100/500 Tablet ER:

Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the Ignalis-M 100/500 Tablet ER whole; avoid chewing, crushing, or breaking it. Administer this extended-release tablet with a meal.

How Ignalis-M 100/500 Tablet ER works:

Ignalis-M 100/500 Extended-Release tablets contain sitagliptin and metformin, working synergistically to manage blood glucose. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and decreases hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and increases insulin sensitivity. This dual-action approach leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent alcohol use with Ignalis-M 100/500 Tablet ER poses a safety risk.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Ignalis-M 100/500 tablets may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescribing. Physician consultation is advised.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Ignalis-M 100/500 tablets are likely unsafe for breastfeeding mothers. Available human data indicates potential transfer of the medication into breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.

KidneyKidneyCAUTION

Patients with kidney impairment should exercise caution when using Ignalis-M 100/500 ER tablets, as dose modification may be necessary. Consult your physician for guidance. Ignalis-M 100/500 ER tablets are contraindicated in patients with severe kidney disease. Routine monitoring of renal function is recommended during treatment.

LiverLiverUNSAFE

Extended-release Ignalis-M 100/500 tablets are contraindicated in individuals with hepatic impairment and should be omitted. Physician consultation is recommended.

What if you forget to take Ignalis-M 100/500 Tablet ER :

Should you forget a dose of Ignalis-M 100/500 Tablet ER, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Ignalis-M 100/500 Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Ignalis-M 100/500 Tablet ER

Ignalis-M 100/500 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Prolonged use of Ignalis-M 100/500 Tablet ER can lead to vitamin B12 deficiency by hindering its absorption. This deficiency, if left untreated, may result in anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and gait instability), urinary issues, and cognitive changes. To mitigate this risk, supplemental vitamin B12 is recommended annually by some researchers.
Ignalis-M 100/500 Tablet ER may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 100/500 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis, should not use this medication.
Combining Ignalis-M 100/500 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Lactic acidosis, a serious medical emergency (also known as MALA, or Metformin-associated lactic acidosis), is a possible side effect of Ignalis-M 100/500 Tablet ER. This condition, resulting from excessive blood lactic acid, is rare but warrants caution in patients with kidney disease, the elderly, or those who consume large quantities of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. Should these symptoms occur, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Ignalis-M 100/500 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Ignalis-M 100/500 Tablet ER may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 100/500 Tablet ER components or excipients, or with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis, should not use this medication.
Combining Ignalis-M 100/500 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA when linked to metformin), is a potential side effect of Ignalis-M 100/500 Tablet ER. This rare complication is more likely in patients with kidney disease, the elderly, or those who consume significant amounts of alcohol, thus necessitating avoidance in these groups. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. Should these symptoms appear, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged use of Ignalis-M 100/500 Tablet ER can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate this risk, supplemental vitamin B12 is recommended annually by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication; keep it out of reach of children, pets, and others.
Ignalis-M 100/500 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Ignalis-M 100/500 Tablet ER may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects include lactic acidosis. Prolonged use can result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 100/500 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis, should not use this medication.
Combining Ignalis-M 100/500 Tablet ER with alcohol is unsafe and may raise your risk of lactic acidosis.
Lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA when linked to metformin), is a potential side effect of Ignalis-M 100/500 Tablet ER. This rare complication is more likely in individuals with kidney disease, the elderly, or those consuming significant alcohol. Symptoms can include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Ignalis-M 100/500 Tablet ER use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
Ignalis-M 100/500 Tablet ...
137
MRP 159
13% off